Enjaymo Marks Latest Milestone In Sanofi’s Blood Disorder Effort

The company plans to draw on experience with other rare blood disorder drug launches, but pointed to some differences in the market for cold agglutinin disease.

3-D Rendering Red Blood Cells
Sanofi won approval for Enjaymo in cold agglutinin disease • Source: Shutterstock

Sanofi will seek to draw from its experience with other drugs that treat rare blood disorders as it launches Enjaymo (sutimlimab-jome) as the sole drug approved to treat cold agglutinin disease (CAD), and the latest in the company’s efforts to build a rare blood disease franchise.

Enjaymo received US Food and Drug Administration approval on 4 February to decrease the need for red blood cell transfusion...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from New Products

More from Scrip